Promoter region methylation of the WRN gene has been reported frequently in colorectal (37.9%), non-small cell lung (37.5%), gastric (25%), prostate (20%), breast (17.2%), and thyroid (12.5%) cancers, chondro-sarcomas (33.3%), and non-Hodgkin lymphoma (23.7%) [47]. This evidence concerns the gene WRN and cancer.